Trade Bristol Myers ^BMY

A Look At Bristol Myers Squibb (BMY) Valuation After US Tariff Threats Hit Pharma Stocks

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial

SteelPeak Wealth LLC Purchases New Holdings in Bristol Myers Squibb Company $BMY

Is Positive Camzyos Adolescent Trial Data Altering The Investment Case For Bristol-Myers Squibb (BMY)?

Bristol-Myers Squibb Cancer Moves And Equity Efforts Underpin Valuation Case

Best Pharmaceutical Stocks To Follow Today - April 3rd - Markets Daily

Bristol Myers Squibb Company $BMY Shares Bought by FNY Investment Advisers LLC

Bristol Myers Squibb Company $BMY Shares Sold by Compagnie Lombard Odier SCmA

Aberdeen Group plc Has $183.23 Million Holdings in Bristol Myers Squibb Company $BMY

Bristol Myers Squibb Company (NYSE:BMY) Receives Average Rating of "Hold" from Analysts

Target product profiles for treatments to delay or prevent symptomatic Alzheimer's disease

David Elkins Sells 30,000 Shares of Bristol Myers Squibb (NYSE:BMY) Stock

Bristol Myers Squibb, Gilead Sciences to review media accounts

Stomach Cancer Market Insights, Trends and Innovations Worldwide, 2026-2030 & 2035

Bristol-Myers Squibb (BMY) Announces Positive Data from the Phase 3 SCOUT-HCM Trial of Camzyos

Glioblastoma Multiforme Market Intelligence Report 2026-2030 & 2035: Advanced Targeted Drugs Propel Industry Growth

Head and Neck Squamous Cell Carcinoma Market Forecast to 2030 & 2035

3 Value Stocks Walking a Fine Line

20,914 Shares in Bristol Myers Squibb Company $BMY Acquired by J. Safra Sarasin Holding AG - Markets Daily

F&V Capital Management LLC Boosts Holdings in Bristol Myers Squibb Company $BMY

Janux nominates development candidate under BMS collaboration | BioWorld

Bristol Myers Squibb Target of Unusually High Options Trading (NYSE:BMY) - Daily Political

Three Seasons Wealth LLC Makes New $872,000 Investment in Bristol Myers Squibb Company $BMY

Bristol Myers Squibb Evolves and Expands Standing in the Ga

Rapid Growth in Paclitaxel Injection Market: From $7.68 Billion in 2026 to $12.72 Billion by 2030

Bristol Myers Squibb Company $BMY Shares Bought by Nisa Investment Advisors LLC

Bristol Myers Squibb Company $BMY Shares Sold by Meyer Handelman Co.

Three Seasons Wealth LLC Buys New Stake in Bristol Myers Squibb Company $BMY - Stock Observer

Camzyos Adolescent Trial Success Might Change The Case For Investing In Bristol-Myers Squibb (BMY)

Is Bristol Myers Squibb (BMY) Price Near US$60 Supported By Cash Flow And Earnings Models

Kidney Cancer Drugs Market to Grow by $2 Billion During 2026-2030: Pfizer, Novartis, Exelixis, Roche, Bristol Myers Squibb Company, and Bayer Lead the Industry

Ariel Global Fund Re-Added Bristol-Myers Squibb Company (BMY) on Pipeline Strength and Attractive Valuation

Ovarian Cancer Drugs Market Outlook Report 2026-2030 Featuring Strategic Analysis of AstraZeneca, Roche, Bristol-Myers Squibb Company, Clovis Oncology, Pfizer and Other Key Players

Retirement Systems of Alabama Boosts Position in Bristol Myers Squibb Company $BMY

Bristol Myers Squibb Company $BMY Shares Purchased by Retirement Systems of Alabama - Daily Political

Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC

MOAT ETF Is Down 7% in 2026. Here Is the Macro Signal That Changes Everything

Advanced Melanoma Markets and Companies 2026-2030: Cumulative Revenue to Grow by $1.87 Billion

Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR During 2026-2030, Led by Pfizer, Roche, Merck & Co., Sanofi, Bristol-Myers Squibb, AstraZeneca, Novartis, and GlaxoSmithKline

Paranasal Sinus Cancer Markets and Competition Outlook 2026-2030 - Precision Oncology, Minimally Invasive Surgeries, and Expanded Cancer Care Models Drive Revenue Growth

Recurrent Head and Neck Cancer Squamous Cell Carcinoma Markets and Competition Outlook 2026-2030: Personalized Medicine Drives Revenue Growth, Reaching $4.61 Billion by 2030

Non-Small Cell Lung Cancer (NSCLC) Global Market Trends and Regional Growth Insights 2026-2030: Rapid Adoption of Targeted Therapies and Immunotherapy Fuels Market Expansion, Reaching $70.8 Billion by 2030

Exchange Traded Concepts LLC Decreases Stock Holdings in Bristol Myers Squibb Company $BMY

1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm

Northwest Wealth Management LLC Makes New $689,000 Investment in Bristol Myers Squibb Company $BMY - Stock Observer

Bristol-Myers Squibb Gets FDA Approval for Hodgkin's Lymphoma Treatment

15 Large-cap Stocks with Highest Dividends

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial

Is Bristol-Myers Squibb Company (BMY) A Good Stock To Buy Now?

Cobenfy Phase 4 Data May Reframe Bristol Myers Squibb Valuation Story

Trial met its primary endpoint, demonstrating clinically mea

Precision Medicine Breakthrough: Mavacamten Markedly Reduces Heart Obstruction in Teens with Hypertrophic Cardiomyopathy

Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) | Morningstar

Bristol Myers announces data from Phase 4 trial of Cobenfy | Markets Insider

Bristol-Myers Squibb Company (NYSE:BMY) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

A Look At Bristol Myers Squibb (BMY) Valuation As Growth Portfolio Outperforms Recent GAAP Loss

Bristol-Myers Squibb (BMY) Faces Mixed Analyst Sentiment Despite Strong Momentum in Healthcare Industry

Wedge Capital Management L L P NC Decreases Stake in Bristol Myers Squibb Company $BMY

Top Pharmaceutical Stocks To Watch Today - March 25th - Markets Daily

PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026

Nepsis Inc. Acquires 90,852 Shares of Bristol Myers Squibb Company $BMY

High treatment completion and no discontinuations due to lac

Top 10 Stocks to Invest in For Financial Stability

Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride) | Morningstar

Bristol Myers Squibb Company $BMY Shares Sold by Wedge Capital Management L L P NC - Stock Observer

Kaufman Rossin Wealth LLC Invests $629,000 in Bristol Myers Squibb Company $BMY - Stock Observer

ET Pharma: Pharma News | Latest Pharma Sector Information and Updates

Jim Cramer on Bristol-Myers Squibb: "The Stock's Recent Pullbacks Have Represented Terrific Buying Opportunities"

Anti-Cancer MAbS Market Report 2026-2030 Featuring Strategic Analysis of Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, Roche, GlaxoSmithKline and Other Key Players

Oncology Precision Medicine Market Trends and Investment Opportunities 2026-2030 - Advancements in CAR-T and Gene Therapies Propel Precision Oncology Growth

A Look At Bristol Myers Squibb (BMY) Valuation As Shares Show Mixed Recent Returns

A New Era in Schizophrenia Care: National Council for Menta

Global X Japan Co. Ltd. Raises Stock Position in Bristol Myers Squibb Company $BMY - Stock Observer

BMS-986482 induces pan-IKZF degradation and robust tumor growth inhibition | BioWorld

Metastatic Triple-Negative Breast Cancer Market: Strong Growth Potential Across APAC Through 2036, Driven by Innovation and Rising Disease Burden | DelveInsight

Stocks making big moves yesterday: Robinhood, Payoneer, Micron, Limbach, and Bristol-Myers Squibb

Expanded Opdivo Use and New Camzyos Data Could Be A Game Changer For Bristol Myers Squibb (BMY)

Bristol Myers Squibb Company $BMY Position Raised by Czech National Bank

Erste Group Bank Has Positive Outlook of BMY FY2026 Earnings - Daily Political

Moody National Bank Trust Division Has $1.32 Million Stake in Bristol Myers Squibb Company $BMY - Daily Political

Why Bristol-Myers Squibb (BMY) Stock Is Up Today

SCHD Annual Reconstitution: Here's What This Dividend ETF Looks Like Now - AOL

Top Pharmaceutical Stocks To Watch Today - March 25th - Daily Political

Bristol Myers Squibb Leans On AI ALS Pact As Valuation Question Persists

Pensionfund Sabic Takes $1.85 Million Position in Bristol Myers Squibb Company $BMY - Daily Political

First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial

Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial

Procyon Advisors LLC Sells 20,349 Shares of Bristol Myers Squibb Company $BMY - Markets Daily

Colgate-Palmolive Board And Asia Leadership Shifts Spark Value Questions

What Is Considered a Good Stock Dividend? 2 Healthcare Stocks Fit the Bill.

US Economy on Stagflation Watch: Apollo Global Management's Outlook

AI Podcast: Fresh Insights on Fed Rate Cut Timing - News in a New Way

S&P 500 Earnings Season to Test Rally Amidst Dim Outlook

Week ahead: Magnificent 7 earnings, 2 key inflation reports

Week ahead: Earnings bonanza, ECB decision & US inflation

Week ahead: Megacap tech and 1-in-3 Dow components set to report

Week ahead: Fed to hike 100bps into a recession?

Trump's Sudden Russia Policy Shift: Rubio's Influence and Implications

Global Market Review: Gold Volatility and Tech Stock Surge Amidst Economic Uncertainty

September CPI Data: Inflation Hurdles, Tariff Impacts, and Fed Rate Cut Expectations

Navigating the AI Boom: Strategies for Investors Amid Nvidia's Valuation Surge

Fund Managers Cautious in Q4: AI, Inflation, and Monetary Policy in Focus

US Government Shutdown Threatens October Inflation Data Release

US-EU Relations: Russia Sanctions Unite Despite Trade Tensions

BOJ Warns of Japan Stock Market Overheating, U.S. Trade Policy Risk